Determinants of influenza vaccination in people over 65 years: 20 years is nothing
e201905022
Keywords:
Influenza, Adult vaccination, Vaccination coverage, National Health SurveyAbstract
Background: The effectiveness of the influenza vaccine has made it a recommended intervention for people at high risk, including adults over 65. This work aimed to analyse the trends of annual vaccination rates, and identify subgroups in the population that have a significant risk of not receiving the vaccine.
Methods: For the first objective, the source of information was the data reported by the Ministry of Health. To determine the trends in vaccination an analysis of interrupted time series was conducted. A multivariable logistic regression analysis was carried out with the National Health Survey (ENSE) of 2017 for the second objective.
Results: The rate of influenza vaccination showed an absolute annual decrease of 1,2 points since the 2006-07 season (95% CI: 0,8%, 1,6%). The prevalence of vaccination in 2017 was 54,9%. The variables independently associated with a higher probability of the influenza vaccine were males, older age, born in Spain, having more visits to the doctor, with prescription of medications, having a chronic illness, being non-smoker, and the lower consumption of fruits.
Conclusions: The coverage of the flu vaccine in the population aged 65 and over is not only below the recommendation of the World Health Organization and indicated by the Interterritorial Council of the National Health System, but is significantly decreasing every year. Sub-groups with lover vaccination rates (women, younger than 75 years, foreign born, with less visits to primary care, no prescription of medicines, no chronic diseases, smokers and with higher intake of fruit) should be targets to develop campaigns and programs to increase their uptake of influenza vaccination so it could provide its potential population benefit.
Downloads
References
Belongia EA, Skowronski DM, McLean HQ, Chambers C, Sundaram ME et al. Repeated annual influenza vaccination and vaccine effectiveness: review of evidence. Expert Review of Vaccines 2017; 16(7): 723-36.
Thompson MG, Pierse N, Sue Hang Q, Prasad N, Duque J et al. Influenza vaccine effectiveness in preventing influenza-associated intensive care admissions and attenuating severe disease among adults in New Zealand 2012–2015. Vaccine 2018; 36: 5916–5925
Godoy P, Romero A, Soldevila N, Torner N, Jané M, Martínez A, Caylà JA, Rius C, Domínguez A. Influenza vaccine effectiveness in reducing severe outcomes over six influenza seasons, a case-case analysis, Spain, 2010/11 to 2015/16. Euro Surveill. 2018;23(43):pii=1700732
World Health Organization. Vaccines against influenza WHO position paper—November 2012. Wkly Epidemiol Rec 2012;87(47):461–76.
Larrauri A, Gherasim A, Delgado C, Oliva J, Pozo F, Casas I. Efectividad de la vacuna antigripal 2017-18 en España. Estimaciones preliminares, semana 44/2017-semana 03/2018 (30 de octubre- 21 de enero 2018). ISCIII, 2018.
Sarría-Santamera A, Timoner J. Influenza vaccination in old adults in Spain. European Journal Public Health 2003;13.:133-7.
Consejo Interterritorial del Sistema Nacional de Salud. Recomendaciones de vacunación frente a la gripe. Temporada 2018-2019.
European Centre for Disease Prevention and Control. Seasonal influenza vaccination in Europe. Vaccination recommendations and coverage rates in the EU Member States for eight influenza seasons: 2007–2008 to 2014–2015. Stockholm: ECDC; 2017.
Corey White, 2018. Measuring the Social and Externality Benefits of Influenza Vaccination Working Papers 1803, California Polytechnic State University.
Centro Nacional de Epidemiología. Informe de vigilancia de la gripe en España. Temporada 2017-18. Instituto de Salud Carlos III
Jorgensen P, Mereckiene J, Cotter S, Johansen K, Tsolova S, Brown C.. How close are countries of the WHO European Region to achieving the goal of vaccinating 75% of key risk groups against influenza? Results from national surveys on seasonal influenza vaccination programmes, 2008/2009 to 2014/2015. Vaccine 2018;36:442-452.
Sarria Santamera A, Timoner J. Determinantes de la vacunación en personas mayores de 65 años. Rev. Esp. Salud Publica 2002; 76(1): 17-26.
Hellfritzsch M, Thomsen RW, Baggesen LM, Larsen FB, Sørensen HT, Christiansen CF. Lifestyle, socioeconomic characteristics, and medical history of elderly persons who receive seasonal influenza vaccination in a tax-supported healthcare system. Vaccine. 2017 Apr 25;35(18):2396-2403
Lu PJ, Rodriguez-Lainz A, O’Halloran A, Greby S, Williams WW.Adult vaccination disparities among foreign born populations in the United States, 2012. Am J Prev Med. 2014; 47(6): 722–733.
Ganczak M, Gil K, Korzeń M, Bażydło M. Coverage and Influencing Determinants of Influenza Vaccination in Elderly Patients in a Country with a Poor Vaccination Implementation. Int J Environ Res Public Health 2017; 14(6): 665.
Larson H, de Figuereido A, Karafllaikis E, Rawal M. State of vaccine confidence in the EU 2018. European Commision
Schmid P, Rauber D, Betsch C, Lidolt G, Denker ML. Barriers of Influenza Vaccination Intention and Behavior - A Systematic Review of Influenza Vaccine Hesitancy, 2005 - 2016. PLoS One 2017;12(1):e0170550.
Rondy M, Kissling E, Emborg H-D, Gherasim A, Pebody R, Trebbien R, et al. Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies. Eurosurveillance. 2018
Preaud E, Durand L, Macabeo B, Farkas N, Sloesen B, Palache A, et al. Annual public health and economic benefits of seasonal influenza vaccination: a European estimate. BMC public health. 2014; 14: 813 10.1186/1471-2458-14-813
Lu PJ, Srivastav A, Amaya A, Dever JA, Roycroft J, Kurtz MS, O’Halloran A, Williams WW. Association of provider recommendation and offer and influenza vaccination among adults aged ≥18 years - United States. Vaccine. 2018;36(6):890-898.
Torner N, Godoy P, Soldevila N, Toledo D, Rius C, Domínguez A. Estudio actitudes sobre vacunación antigripal en profesionales sanitarios de atención primaria de Cataluña. Aten Primaria 2016;48: 192-199.
McCartney M. Margaret McCartney: Mandatory flu vaccination won’t fix the NHS. BMJ. 2018;k402.
House of Commons, Science and Technology, Committee. Flu vaccination programme in England. 2018.
Suppli CH, Hansen ND, Rasmussen M, Valentiner-Branth P, Krause TG, Mølbak K. Decline in HPV-vaccination uptake in Denmark – the association between HPV-related media coverage and HPV-vaccination. BMC Public Healt 2018;18(1).
Comisión Europea. Panel de expertos para vías efectivas de invertir en salud. Vaccination programmes and health systems in the European Union. 2018.
Karafillakis E, Larson HJ; ADVANCE consortium. The benefit of the doubt or doubts over benefits? A systematic literature review of perceived risks of vaccines in European populations. Vaccine. 2017;35(37):4840-4850.
NICE. Flu vaccination: increasing uptake (NG103). Public Health England, 2018.
Fullaondo A. CHRODIS+ Implementation strategy. Kick-off event. Disponible en: http://chrodis.eu/wp-content/uploads/2017/10/chrodis_plus-kronigue.pdf
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2019 Antonio Sarría-Santamera, Francisco Rodríguez-Cabrera, Patricia González Soriano, Lorena Pinilla Navas, Teresa Corral Canto
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Usted es libre de:
Compartir — copiar y redistribuir el material en cualquier medio o formato.
La licenciante no puede revocar estas libertades en tanto usted siga los términos de la licencia.
Bajo los siguientes términos:
Atribución — Usted debe dar crédito de manera adecuada , brindar un enlace a la licencia, e indicar si se han realizado cambios. Puede hacerlo en cualquier forma razonable, pero no de forma tal que sugiera que usted o su uso tienen el apoyo de la licenciante.
NoComercial — Usted no puede hacer uso del material con propósitos comerciales.
SinDerivadas — Si remezcla, transforma o crea a partir del material, no podrá distribuir el material modificado.
No hay restricciones adicionales — No puede aplicar términos legales ni medidas tecnológicas que restrinjan legalmente a otras a hacer cualquier uso permitido por la licencia.
Avisos:
No tiene que cumplir con la licencia para elementos del material en el dominio público o cuando su uso esté permitido por una excepción o limitación aplicable.
No se dan garantías. La licencia podría no darle todos los permisos que necesita para el uso que tenga previsto. Por ejemplo, otros derechos como publicidad, privacidad, o derechos morales pueden limitar la forma en que utilice el material.
